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Brief Communication
Effect of Epigallocatechin-3-Gallate on Graft-Versus-Host Disease
Jaebok Choi,* Matthew L. Cooper,* Edward D. Ziga,†1 Julie Ritchey,* and John F. DiPersio*
*Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
†Division of Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by alloreactive donor
T-cell-mediated graft-versus-host disease (GvHD). The major polyphenol of green tea, epigallocatechin-3gallate (EGCG), is an inhibitor of both DNA methyltransferase 1 (DNMT1) and signal transducer and activator
of transcription 1 (STAT1), which are essential for induction of GvHD. Thus, in this report, we examine if
in vivo administration of EGCG mitigates GvHD in several different animal models. While we concede that
refinement of EGCG treatment might result in GvHD prevention, our results suggest that EGCG treatment
might not be an effective therapy against GvHD in the clinic.
Key words: Graft-versus-host disease (GvHD); Allogeneic hematopoietic stem cell transplantation (allo-HSCT);
Epigallocatechin-3-gallate (EGCG); DNA methyltransferase 1 (DNMT1); Interferon-g receptor signaling;
Signal transducer and activator of transcription 1 (STAT1)

INTRODUCTION
We recently reported that azacitidine (AzaC), a DNA
methyltransferase 1 (DNMT1) inhibitor, and INCB018424,
an inhibitor of janus kinase 1 (JAK1)/JAK2, which mediate interferon-g receptor (IFN-g R) signaling via signal
transducer and activator of transcription 1 (STAT1) phosphorylation, mitigate graft-versus-host disease (GvHD)
while maintaining antileukemia effects (graft-versusleukemia effect or GvL) after allo-hematopoietic stem
cell transplantation (allo-HSCT) (1,2). The major polyphenol of green tea, epigallocatechin-3-gallate (EGCG),
has been shown to be an inhibitor of both DNMT1 and
STAT1 (4,8,9,13), thereby being a very attractive potential therapeutic agent to prevent or treat GvHD after alloHSCT.
Hyon and colleagues have proposed that EGCG
inhibits T-cell activation in vitro (7) and that EGCGtreated T-cells are less potent at inducing GvHD in vivo
(5) acting through the blockade of stimulatory receptors.
The authors’ data have drawn attention to EGCG in the

field of GvHD. Their in vitro proliferation analyses are
both impressive and compelling. While EGCG-treated
allogeneic splenocytes result in a significantly improved
survival according to their most recent report, the benefit
of EGCG in survival was minimal: median survival of 8
days (untreated) versus 10 days (EGCG) (5). Moreover,
all the recipient mice died within 16 days of transplantation, perhaps due to the ineffectiveness of EGCG on
blocking GvHD or partly because bone marrow cells
were not transplanted along with splenocytes; thus, it is
unclear whether the major cause of death was GvHD. In
addition, the method used (in vitro incubation of purified donor C57BL/6 splenocytes incubated for 1 h at
4°C with 200 µM EGCG prior to infusion into Balb/c
recipients) would be costly and time consuming when
translated into the clinic. Therefore, in this report, we
utilized a more clinically preferred method, that is, in
vivo administration of EGCG into allogeneic recipients,
to test if EGCG treatment results in reduced GvHD after
allo-HSCT.
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Figure 1. Effect of EGCG on GvHD. T-cell-depleted bone marrow (TCD BM) cells (5 × 106) [major histocompatibility complex class II H-2b, cluster of differentiation 45.1 positive (CD45.1+)] along with pan T-cells (H-2b, CD45.2+; 5 × 105 T-cells for Balb/c and 5 × 106 for C57BL/6×129) isolated from C57BL/6 donor mice were intravenously transplanted
into Balb/c recipient mice (H-2d, CD45.2+) (A), which were lethally irradiated 1 day prior to the allo-hematopoietic stem cell transplantation (allo-HSCT) (925 cGy from a 137Cs
source), or into C57BL/6x129 F1 (1,200 cGy; H-2b, CD229.1+) (B). Epigallocatechin-3-gallate [EGCG; 100 μg in 10% dimethyl sulfoxide (DMSO) in phosphate-buffered saline
(PBS)] was intraperitoneally (IP) injected twice a day for 21 days starting day 0 post-allo-HSCT. (C) Human pan T-cells (3 × 106) were retro-orbitally transplanted on day 0 into
sublethally irradiated (250 cGy on day −1) nonobese diabetic/severe combined immunodeficient interleukin 2 (IL-2) receptor g chain knockout (NSG) mice. EGCG (10−1,000 μg)
was injected IP once every other day for 21 days starting day 3 post-human T-cell injection. XRT: xenotransplantation. Survival was compared using the log-rank test. (D) Donor
mice (C57BL/6), not the recipients, were injected IP with EGCG (100 µg in PBS only) or carrier (PBS) each day for 4 days prior to T-cell harvest from donors. Donor splenocytes
(2 × 107, CD229.2+, CD45.2+) and TCD BM (5 × 106, CD229.2+, CD45.1+) were injected via the lateral tail vein on day 0 into lethally irradiated C57BL/6x129 recipients (1,200 cGy
on day −1; H-2b, CD229.1+).
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EFFECT OF EGCG ON GvHD

MATERIALS AND METHODS
Mice
All mice (6- to 12-week-old males) were obtained from
Jackson Laboratory (Bar Harbor, ME, USA). Animal
study protocols including animal care and euthanasia
were approved by the Washington University School of
Medicine Animal Studies Committee.
Cells
Human peripheral blood mononuclear cells (PBMCs)
were collected in compliance with the protocols outlined by the Washington University School of Medicine
Human Studies Committee and harvested by Ficoll (GE
Healthcare Bio-science AB, Uppsala, Sweden) gradient centrifugation. Human pan T-cells were isolated
from the human PBMCs using Miltenyi microbeads and
AutoMACS (Miltenyi Biotech, Auburn, CA, USA) (10).
Mouse pan T-cells were isolated from mouse spleens
using Miltenyi microbeads and an AutoMACS (Miltenyi
Biotech) (10).
EGCG
EGCG was purchased from Sigma (St. Louis, MO,
USA) and suspended in either 10% dimethyl sulfoxide
(DMSO; Sigma)/phosphate-buffered saline (PBS; Sigma)
or just PBS, for intraperitoneal injection. See figure legend for additional methods.
RESULTS AND DISCUSSION
We examined whether in vivo administration of EGCG,
which is more clinically relevant than that of EGCGtreated cells, into allo-HSCT recipients reduces GvHD
after allo-HSCT. Intraperitoneal administration of EGCG
has been well documented and proven to be an effective
method of EGCG delivery (3,6,11,12). We tested a fully
major histocompatibility complex (MHC) mismatched
(C57BL/6 to Balb/c) (Fig. 1A), a minor mismatched
(C57BL/6 to C57BL/6x129 F1) (Fig. 1B), and a xenotransplantation model (human T-cells to nonobese diabetic/
severe combined immunodeficient interleukin 2 (IL-2)
receptor g chain knockout [NOD/SCID/gc KO (NSG)]
(Fig. 1C). None of the recipients showed improved survival or a reduction in weight loss, suggesting that EGCG
when given in the dose and schedule shown was not effective in ameliorating GvHD in any of these models. We also
tested whether in vivo administration of EGCG to donor
mice before harvest of donor T-cells could render the donor
T-cells inactive at inducing GvHD when transplanted into
allogeneic recipients (C57BL/6 to C57BL/6x129). Again,
we observed no decrease of GvHD when compared to
T-cells from untreated donor mice (Fig. 1D). Although
we do not exclude a possibility that the doses and timing used here might not be optimal for EGCG to inhibit
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DNMT1 and STAT1 (our hypothesis) or to mask immunostimulatory receptors (5) and concede that refinement
of EGCG treatment might result in GvHD prevention,
our preliminary results do not corroborate or confirm
those of Kanamune et al. (5) and suggest that the effect of
EGCG on GvHD is, at best, minimal. In addition, the current clinical goal is to prevent GvHD while maintaining
GvL, which, like GvHD, is also mediated by alloreactive
donor T-cells. Even though it is conceivable that EGCGtreated T-cells or direct administration of EGCG to recipients might result in a reduction of GvHD, it remains to
be determined whether or not it might also abrogate the
beneficial GvL effect. The “immunocamouflage” of allogeneic T-cell receptors by EGCG, as hypothesized by the
authors (7), is unlikely to result in differential activation
of donor T-cells by tumor-associated antigens and alloantigens on GvHD target organs. Furthermore, based on
the studies by Kanamune et al. (5), it is likely that EGCGtreated T-cells would possess less GvL potential since
their expansion in recipients is highly limited.
In conclusion, although EGCG may be an effective
inhibitor of both DNMT1 and STAT1, the treatment of
EGCG after allo-HSCT does not result in prevention or
reduction of GvHD in four different GvHD models, suggesting that EGCG treatment might not be an effective
therapy against GvHD in the clinic.
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